{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:13:09Z","timestamp":1780492389650,"version":"3.54.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","funder":[{"name":"Toronto General Research Institute"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Network on Hepatitis C","award":["HPC-178912"],"award-info":[{"award-number":["HPC-178912"]}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.<\/jats:p>","DOI":"10.1093\/cid\/ciad336","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:25:51Z","timestamp":1692037551000},"page":"S257-S261","source":"Crossref","is-referenced-by-count":6,"title":["Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-702X","authenticated-orcid":false,"given":"T Jake","family":"Liang","sequence":"first","affiliation":[{"name":"Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L M","family":"Law","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pietschmann","sequence":"additional","affiliation":[{"name":"Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research , Hannover , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C","family":"Ray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital; Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Bull","sequence":"additional","affiliation":[{"name":"Liver Center, Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T","family":"Chung","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences and The Kirby Institute, Medicine and Health, University of New South Wales , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Lorne","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Houghton","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta , Edmonton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M","family":"Rice","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Infectious Disease, The Rockefeller University , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"2023112721314726500_ciad336-B1","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-21","article-title":"Controlled human infection models to accelerate vaccine development","volume":"35","author":"Choy","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2023112721314726500_ciad336-B2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat Med"},{"key":"2023112721314726500_ciad336-B3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/ilar\/ilx028","article-title":"The chimpanzee model of viral hepatitis: advances in understanding the immune response and treatment of viral hepatitis","volume":"58","author":"Lanford","year":"2017","journal-title":"ILAR J"},{"key":"2023112721314726500_ciad336-B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.blre.2019.01.003","article-title":"Genetically-engineered pigs as sources for clinical red blood cell transfusion: what pathobiological barriers need to be overcome?","volume":"35","author":"Smood","year":"2019","journal-title":"Blood Rev"},{"key":"2023112721314726500_ciad336-B5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"2023112721314726500_ciad336-B6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"2023112721314726500_ciad336-B7","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1073\/pnas.0409666102","article-title":"An in vitro model of hepatitis C virion production","volume":"102","author":"Heller","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112721314726500_ciad336-B8","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0511218103","article-title":"Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro","volume":"103","author":"Lindenbach","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112721314726500_ciad336-B9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1\u20137 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"key":"2023112721314726500_ciad336-B10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JVI.02877-14","article-title":"Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77","volume":"89","author":"Li","year":"2015","journal-title":"J Virol"},{"key":"2023112721314726500_ciad336-B11","doi-asserted-by":"crossref","first-page":"19757","DOI":"10.1073\/pnas.1218260109","article-title":"Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112721314726500_ciad336-B12","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"Yi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112721314726500_ciad336-B13","doi-asserted-by":"crossref","first-page":"e1000475","DOI":"10.1371\/journal.ppat.1000475","article-title":"Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations","volume":"5","author":"Pietschmann","year":"2009","journal-title":"PLoS Pathog"},{"key":"2023112721314726500_ciad336-B14","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.3390\/v14112527","article-title":"Novel HCV genotype 4d infectious systems and assessment of direct-acting antivirals and antibody neutralization","volume":"14","author":"Pham","year":"2022","journal-title":"Viruses"},{"key":"2023112721314726500_ciad336-B15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature14899","article-title":"SEC14L2 enables pan-genotype HCV replication in cell culture","volume":"524","author":"Saeed","year":"2015","journal-title":"Nature"},{"key":"2023112721314726500_ciad336-B16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/hep.22422","article-title":"Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation","volume":"48","author":"Kato","year":"2008","journal-title":"Hepatology"},{"key":"2023112721314726500_ciad336-B17","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.03540-13","article-title":"Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee","volume":"88","author":"Yi","year":"2014","journal-title":"J Virol"},{"key":"2023112721314726500_ciad336-B18","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-21","article-title":"Controlled human infection models to accelerate vaccine development","volume":"35","author":"Choy","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2023112721314726500_ciad336-B19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002880","article-title":"Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing","volume":"8","author":"Li","year":"2012","journal-title":"PLoS Pathog"},{"key":"2023112721314726500_ciad336-B20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/jvi.67.4.1953-1958.1993","article-title":"Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes","volume":"67","author":"Hijikata","year":"1993","journal-title":"J Virol"},{"issue":"Suppl 1","key":"2023112721314726500_ciad336-B21","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/cld.882","article-title":"Reflections on the history of HCV: a posthumous examination","volume":"15","author":"Alter","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2023112721314726500_ciad336-B22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1128\/JCM.01229-07","article-title":"Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates","volume":"46","author":"Page-Shafer","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2023112721314726500_ciad336-B23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol Rev"},{"key":"2023112721314726500_ciad336-B24","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112721314726500_ciad336-B25","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/651579","article-title":"Challenge pools of hepatitis C virus genotypes 1\u20136 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models","volume":"201","author":"Bukh","year":"2010","journal-title":"J Infect Dis"},{"key":"2023112721314726500_ciad336-B26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-104-4-488","article-title":"Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood","volume":"104","author":"Koziol","year":"1986","journal-title":"Ann Intern Med"},{"key":"2023112721314726500_ciad336-B27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/infdis\/144.6.588","article-title":"Non-A, non-B hepatitis in chimpanzees and marmosets","volume":"144","author":"Feinstone","year":"1981","journal-title":"J Infect Dis"},{"key":"2023112721314726500_ciad336-B28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.277.5325.570","article-title":"Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA","volume":"277","author":"Kolykhalov","year":"1997","journal-title":"Science"},{"key":"2023112721314726500_ciad336-B29","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.94.16.8738","article-title":"Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee","volume":"94","author":"Yanagi","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112721314726500_ciad336-B30","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J Virol"},{"key":"2023112721314726500_ciad336-B31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2023112721314726500_ciad336-B32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1\u20137 and Escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"2023112721314726500_ciad336-B33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"2023112721314726500_ciad336-B34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-2600(19)30268-1","article-title":"Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial","volume":"8","author":"Cypel","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2023112721314726500_ciad336-B35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/v13050833","article-title":"From structural studies to HCV vaccine design","volume":"13","author":"Yechezkel","year":"2021","journal-title":"Viruses"},{"key":"2023112721314726500_ciad336-B36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.gastro.2019.11.282","article-title":"Antibody responses to immunization with HCV envelope glycoproteins as a baseline for B-cell\u2013based vaccine development","volume":"158","author":"Chen","year":"2020","journal-title":"Gastroenterology"},{"key":"2023112721314726500_ciad336-B37","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1128\/JVI.02700-15","article-title":"A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance","volume":"90","author":"Urbanowicz","year":"2016","journal-title":"J Virol"},{"key":"2023112721314726500_ciad336-B38","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"2023112721314726500_ciad336-B39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"2023112721314726500_ciad336-B40","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"2023112721314726500_ciad336-B41","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1136\/gutjnl-2020-321190","article-title":"Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies","volume":"70","author":"Bankwitz","year":"2021","journal-title":"Gut"},{"key":"2023112721314726500_ciad336-B42","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad362","article-title":"Controlled human infection model for hepatitis C virus vaccine development: trial design considerations","volume":"77","author":"Feld","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_3\/S257\/53845207\/ciad336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_3\/S257\/53845207\/ciad336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T19:23:59Z","timestamp":1729538639000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/Supplement_3\/S257\/7242434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":42,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2023,8,14]]},"published-print":{"date-parts":[[2023,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad336","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,15]]},"published":{"date-parts":[[2023,8,14]]}}}